0001209191-19-015896.txt : 20190304
0001209191-19-015896.hdr.sgml : 20190304
20190304181227
ACCESSION NUMBER: 0001209191-19-015896
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190228
FILED AS OF DATE: 20190304
DATE AS OF CHANGE: 20190304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WU JINN
CENTRAL INDEX KEY: 0001314254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 19655671
MAIL ADDRESS:
STREET 1: 107 MORGAN LANE
CITY: PLAINSBORO
STATE: NJ
ZIP: 08536
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-28
0
0001300699
Athenex, Inc.
ATNX
0001314254
WU JINN
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO
NY
14203
1
0
0
0
Common Stock
321208
D
Stock Option (Right to Buy)
4.55
2013-01-02
2023-01-02
Common Stock
90000
90000
D
Stock Option (Right to Buy)
4.55
2014-02-12
2024-02-12
Common Stock
10000
10000
D
Stock Option (Right to Buy)
5.50
2015-02-05
2025-02-05
Common Stock
54000
54000
D
Stock Option (Right to Buy)
5.50
2017-03-20
2025-03-20
Common Stock
96000
96000
D
Stock Option (Right to Buy)
11.00
2027-06-13
Common Stock
28500
28500
D
Stock Option (Right to Buy)
13.17
2019-02-28
4
A
0
15000
0.00
A
2029-02-28
Common Stock
15000
15000
D
The option vests in four equal annual installments beginning on June 13, 2018.
The option vests in four equal annual installments beginning on February 28, 2020.
/s/ Teresa Bair, Attorney-in-Fact
2019-03-04